WuXi AppTec
2025.09.19
15:09
Unusual movements in call auctions of several large-cap stocks
Several stocks saw significant moves in the closing call auction. Eosun, InnoLight, WuXi AppTec, and BeiGene all rallied, while China National Nuclear Power, China Unicom, and Wanhua Chemical all declined. On a related note, FTSE Russell announced on September 3rd quarterly review changes to the FTSE China 50 and other indices, effective after the market close on September 19th. The FTSE China A50 Index now includes BeiGene-U, Eosun, WuXi AppTec, and InnoLight, while excluding China National Nuclear Power, China Unicom, NARI, and Wanhua Chemical.
2025.09.11
16:10
At the close of Hong Kong stocks, the Hang Seng Index closed down 0.43%, the Sci-Tech Index closed down 0.24%, and the pharmaceutical sector collectively weakened, with WuXi AppTec (02359.HK) closing down 5.65%.
11:23
The Hong Kong stock market saw a collective drop in innovative drug stocks, with unfavorable news coming from the market.
Innovative drug stocks plummeted in early trading on the Hong Kong stock market, with declines exceeding 6% in the oncology, assisted reproductive, innovative drug, and CXO sectors. A-share innovative drug stocks also followed suit, with BeiGene and Innovent Biologics falling over 10%, and Sinopharm, Huahai Pharmaceutical, Chipscreen Biopharma, Rongchang Biopharma, and WuXi AppTec dropping over 6%. Despite negative market news, research institutions strongly advocated for the sell-off, viewing it as a buying opportunity. They also believed that the upward trend in the A-share and Hong Kong pharmaceutical sectors is far from over, and that the main upward trend is expected to continue in the medium to long term. News reports circulated across investment circles that the Trump administration is considering strict restrictions on pharmaceuticals imported from China, including a draft executive order that could disrupt experimental therapies invented in China, potentially impacting the US pharmaceutical industry and limiting the availability of generic drugs and advanced therapies. However, the White House stated that it was not "actively considering" the draft order.
09:38
Hong Kong biopharmaceutical stocks fell collectively, with the Hang Seng Healthcare Index falling 6%.
Hong Kong-listed biopharmaceutical stocks fell collectively, with the Hang Seng Healthcare Index's decline widening to 6%. China Biologic Products and Shijiazhuang Pharmaceutical Group fell more than 10%, Fosun Pharma fell more than 7%, and WuXi Biologics and WuXi AppTec both fell more than 5%.
09:28
Innovative drug concept stocks opened sharply lower, with BeiGene falling over 10%.
Innovative drug concept stocks opened sharply lower, with BeiGene falling more than 10%, WuXi AppTec and Tiger Pharmaceuticals falling more than 7%, and Hengrui Medicine, Junshi Biosciences, and CStone Pharmaceuticals falling more than 5%.
09:28
Many A-share CRO concept stocks opened lower, with WuXi AppTec and Tiger Pharmaceuticals falling more than 7%, Corning Life Sciences falling more than 5%, and Zhaoyan Pharmaceutical, MediSci, and Hengrui Medicine following suit.
09:21
Hong Kong stocks opened: Hang Seng Index opened 0.81% lower, with most new drug concept stocks opening lower
At the Hong Kong stock market opening, the Hang Seng Index opened 0.81% lower, and the Hang Seng Tech Index opened 0.97% lower. Most innovative drug stocks opened lower, with WuXi Biologics down 9.52%, BeiGene down 9.32%, and WuXi AppTec down 6.95%.
2025.09.08
09:46
The Hong Kong stock market's biopharmaceutical sector continued to strengthen, with WuXi AppTec (02359.HK) rising more than 5%, Fuhong Hanlin (02696.HK) rising more than 4%, Zai Lab (09688.HK), WuXi Biologics (02269.HK) and others following suit.
2025.09.05
16:10
Hong Kong Stock Market Close Review: Hang Seng Index rose 1.43%, Hang Seng Tech Index rose 1.95%
At the close of Hong Kong trading, the Hang Seng Index rose 1.43%, while the Hang Seng Tech Index rose 1.95%. The Hong Kong Tech ETF (159751) rose 2.5%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose 1.54%. Among sectors, biotechnology and semiconductor products and equipment led the gains. In terms of individual stocks, Horizon Robotics-W rose 9.12%, Kelun Botai Bio-B rose 6.63%, China Biologic Products rose 6.2%, China Aluminum Corporation rose 6.12%, Hengrui Medicine rose 5.96%, Shandong Gold rose 5.87%, Zijin Mining rose 5.85%, Luoyang Molybdenum Co., Ltd. rose 5.77%, China Hongqiao rose 5.14%, Kangfang Biopharmaceuticals rose 5.09%, SMIC rose 4.82%, WuXi Biologics rose 4.71%, Hansoh Pharmaceutical rose 4.56%, Zhaojin Mining rose 4.44%, Kuaishou-W rose 4.36%, WuXi AppTec rose 4.22%; Gemdale Properties fell 4.49%, Uni-President Enterprises China fell 4.62%; China Innovation Aviation rose 18.37%, and Sansure Pharmaceutical rose 18.24%.
16:10
At the close of Hong Kong stocks, the Hang Seng Index rose 1.43%, and the Tech Index rose 1.95%. Horizon Robotics (09660.HK) rose over 9%, while WuXi AppTec (02359.HK) and Kuaishou (01024.HK) rose over 4%.
14:27
The A-share innovative drug sector continued to rise, with Zejing Pharmaceutical rising more than 15%, Sunbet Biotech and Haichen Pharmaceutical rising more than 11%, Borrui Pharmaceutical and Zhaoyan Pharmaceutical rising more than 9%, and Changchun High-Tech, Junshi Biosciences, and WuXi AppTec following suit.
2025.09.04
13:37
The A-share pharmaceutical and biological sector fluctuated downward, with Sanyou Medical falling more than 13%, WuXi AppTec and Biologics falling more than 9%, and Maiwei Biopharmaceuticals and Nanxin Pharmaceutical falling more than 8%.
10:31
Hong Kong-listed innovative drug concept stocks fell collectively, with Zai Lab (09688.HK) down more than 11%, Hengrui Medicine (01276.HK), Ascletis Pharma (01672.HK), and Everest Medicines (01952.HK) down more than 5%, WuXi AppTec (02359.HK) down more than 4%, Innovent Biologics (01801.HK), WuXi Partners (02268.HK), and Hansoh Pharmaceutical (03692.HK) down more than 3%.
2025.09.02
17:23
WuXi AppTec: Subsidiary equity transferred to a newly established wholly-owned subsidiary
WuXi AppTec announced plans to transfer its 98.9% stake in Shanghai Hequan Pharmaceuticals, held by Shanghai WuXi, to WuXi AppTec (Shanghai) Pharmaceutical Research & Development Co., Ltd. Upon completion of this equity transfer, WuXi Research & Development will directly hold 98.9% of the target company's shares. This equity transfer will not affect the scope of the company's consolidated financial statements, the substantive operations of the target company, or its profits or overall equity.
17:23
WuXi AppTec: Signed a Supplemental Agreement to the Payload Connector Master Services Framework Agreement with its Affiliate XDC Cayman
WuXi AppTec announced that it has signed a Supplemental Agreement to the Payload Connectivity Sub-Master Services Framework Agreement with its related party, XDC Cayman, increasing the 2025 related-party transaction limit from 168 million yuan to 200 million yuan. Additionally, the company and XDC Cayman signed a new three-year Payload Connectivity Sub-Master Services Framework Agreement, effective from January 1, 2026, to December 31, 2028. The annual transaction amounts for 2026, 2027, and 2028 are expected to be no more than 300 million yuan, 400 million yuan, and 400 million yuan, respectively. The company stated that this transaction is a normal commercial arrangement in its daily operations and will not affect its independence.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Musk: XAI will certainly raise funds in the next few months, but not now

2025-09-20

Nvidia (NVDA.O) fell further, dropping nearly 3%.

2025-09-17

SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.

2025-09-18

HGTECH's 3.2T NPO products are used by leading industry customers

2025-09-24

Alipay's two operating entities have completed the name change

2025-09-19

ASIA TECH WIRE

Grasp technology trends

Download